CLEVELAND, May 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that UCI Health has purchased a MRIdian MRI-guided radiation therapy system for its new Chao Family Comprehensive Cancer Center and Ambulatory Care and will soon be offering advanced ViewRay MRIdian SMART MRI-guided radiation therapy.
UCI Health is the clinical enterprise of the University of California, Irvine. As Orange County's only academic health system, UCI Health is dedicated to the discovery of novel therapies, teaching future healers and delivering of the finest evidence-based care. Its new Chao Family Comprehensive Cancer Center and Ambulatory Care is one of three medical facilities at the $1.3 billion medical center under construction adjacent to the UCI campus. It is scheduled to open in late 2023.
"As Orange County's only National Cancer Institute-designated comprehensive cancer center, we treat more complex cases than any other healthcare provider in the region," said Dr. Allen Chen, chair of the UCI Health Department of Radiation Oncology. "The addition of MRI-guided radiation therapy technology at the new medical center will increase treatment options for patients who need personalized cancer therapy for a variety of hard-to-target cancers."
Ad Statistics
Times Displayed: 194156
Times Visited: 5654 For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
"We are delighted to announce UCI Health's purchase of the MRIdian SMART MRI-guided radiation therapy system. The system brings the benefits of stereotactic MR-guided adaptive radiotherapy to one of the most innovative cancer centers in the world," said Paul Ziegler, Chief Commercial Officer of ViewRay. "MRIdian permits cutting-edge clinical research projects with enhanced real-time MRI imaging, while addressing the complex needs of even more cancer patients."
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.
Over 21,000 patients have been treated with MRIdian. Currently, 50 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
